Company : Part I. Annual Pharmaceutical R&D Expenditures, 1990-2010 A. Total, NCE, and Other R&D Expenditures (millions of dollars) (3) (2) R&D on R&D on Self- (5) (1) Originated Therapeutic Therapeutc New (4) R&D on (6) (7) Total New Chemical Entities Biologics R&D on New NCE R&D on R&D on (NCEs) [excluding Originated New and Biologic Licensed Existing R&D (pre-approval) vaccines] Vaccines Diagnostics Compounds Products Year (pre-approval) (pre-approval) (pre-approval) (pre-approval) (post-approval) 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Company : Part I. Annual Pharmaceutical R&D Expenditures, 1990-2010 A. Total, NCE, and Other R&D Expenditures (millions of dollars) Year (1) Total R&D (2) R&D on Therapeutic New Chemical Entities (NCEs) (pre-approval) (3) R&D on Self- Originated Therapeutc New Biologics [excluding vaccines] (pre-approval) (4) R&D on New Vaccines (pre-approval) (5) R&D on New NCE and Biologic Diagnostics (pre-approval) (6) R&D on Licensed Compounds (pre-approval) (7) R&D on Existing Products (post-approval) 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Originated
1-s2.0-S0167629616000291-mmc1.docx